Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease
Open Access
- 30 August 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2021.00201
Abstract
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease and affects at least a quarter of the global adult population. It has rapidly become one of the leading causes of hepatocellular carcinoma and cirrhosis in Western countries. In this review, we discuss the nomenclature and definition of MAFLD as well as its prevalence and incidence in different geographical regions. Although cardiovascular disease remains the leading cause of death in MAFLD patients, the proportion of patients dying from hepatic complications increases sharply as the disease progresses to advanced liver fibrosis and cirrhosis. In addition, patients with MAFLD are at increased risk of various extrahepatic cancers. Although a causal relationship between MAFLD and extrahepatic cancers has not been established, clinicians should recognize the association and consider cancer screening (e.g., for colorectal cancer) as appropriate.Keywords
This publication has 128 references indexed in Scilit:
- Medical Risk Factors Associated with Cholangiocarcinoma in Taiwan: A Population-Based Case-Control StudyPLOS ONE, 2013
- International Variation in Prostate Cancer Incidence and Mortality RatesEuropean Urology, 2012
- Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohortJournal of Hepatology, 2012
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2010
- Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levelsJournal of Hepatology, 2009
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005Journal of Clinical Oncology, 2009
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma in the United States: A Population-Based Case-Control StudyClinical Gastroenterology and Hepatology, 2007
- Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter studyJournal of Hepatology, 2006
- Prevalence of and risk factors for fatty liver in a general population of Shanghai, ChinaJournal of Hepatology, 2005